Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 16/20 | 0.63 |
| ▸ | PDE3A | Q14432 | 16/20 | 0.63 |
| ▸ | PDE4A | P27815 | 4/20 | 0.49 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3242923 | 0.92 | PDE4B (0.69) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3238687 | 0.91 | PDE4B (0.61) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3238929 | 0.90 | PDE4B (0.60) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3240572 | 0.89 | PDE4B (0.64) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3115295 | 0.88 | PDE4B (0.49) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3115208 | 0.84 | PDE4B (0.61) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3129036 | 0.84 | PDE4B (0.61) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL2845152 | 0.82 | PDE4B (0.62) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3114277 | 0.82 | PDE4B (0.59) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL3111423 | 0.80 | PDE4B (0.54) | PDE4BPDE3APDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160335-A1 | PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | PDE3A, PDE5A, PDE2A | PDE4B 8/4885PDE3A 1/4885PDE4A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.